This Fund Has a $200 Million Bet on a Biotech Stock Up 30% in Days After Phase 3 BreakthroughThe Motley Fool • 03/13/26
Xenon Pharmaceuticals Announces Closing of $747.5 Million Upsized Public Offering Including Full Exercise of the Underwriters' Option to Purchase Additional SharesGlobeNewsWire • 03/12/26
Xenon Pharmaceuticals Announces Pricing of Upsized $650.0 Million Public OfferingGlobeNewsWire • 03/11/26
XENE Stock Up as Azetukalner Meets Goal in Focal Onset Seizures StudyZacks Investment Research • 03/10/26
Xenon Pharmaceuticals Inc. (XENE) Discusses Positive Top Line Results from Phase 3 X-TOLE2 Study of Azetukalner in Focal Onset Seizures TranscriptSeeking Alpha • 03/09/26
Xenon Pharmaceuticals Rallies After Pivotal Data Shows Major Drop In Monthly SeizuresBenzinga • 03/09/26
The 'Unprecedented' Results That Could Nab Xenon A GW- Or Intra-Cellular-Like DealInvestors Business Daily • 03/09/26
Xenon Announces Positive Topline Data from Phase 3 X-TOLE2 Study of Azetukalner in Focal Onset Seizures (FOS)GlobeNewsWire • 03/09/26
Xenon to Announce Topline Results from Phase 3 X-TOLE2 Study of Azetukalner in Focal Onset Seizures on Monday, March 9, 2026GlobeNewsWire • 03/08/26
Xenon Reports Q4 and Full Year 2025 Financial Results and Provides Business UpdateGlobeNewsWire • 02/26/26
Xenon Stock at $42: What to Know of a $75 Million Trim Ahead of March Phase 3 DataThe Motley Fool • 02/19/26
Polarean Expands Xenon MRI Platform into Cardiopulmonary Drug Development with Multi-Center PH-ILD StudyGlobeNewsWire • 01/20/26
Xenon Pharmaceuticals Inc. (XENE) Presents at 44th Annual J.P. Morgan Healthcare Conference TranscriptSeeking Alpha • 01/12/26
Xenon Outlines Key Upcoming Milestones at the 2026 J.P. Morgan Healthcare ConferenceGlobeNewsWire • 01/12/26
Xenon Pharmaceuticals: Derisked Pipeline Ahead Of Critical 2026 Phase 3 ReadoutSeeking Alpha • 12/18/25
Xenon Pharmaceuticals Inc. (XENE) Discusses Latest Phase III Updates for Azetukalner in Epilepsy and Commercial Launch Preparation TranscriptSeeking Alpha • 12/10/25
Xenon Showcases New 48-Month Azetukalner OLE Study Data in Epilepsy at AES 2025GlobeNewsWire • 12/05/25